On March 8, 2022 Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, reported the publication of two abstracts that have been accepted for poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, which is taking place both virtually and in-person at the Ernest N. Morial Convention Center in New Orleans, Louisiana from April 8-13, 2022 (Press release, Cardiff Oncology, MAR 8, 2022, View Source [SID1234609725]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The full texts of the published abstracts can be found on the AACR (Free AACR Whitepaper) Annual Meeting website. Details on the corresponding posters are shown below.
Poster Title:
Biomarkers of response to abiraterone and the polo-like kinase 1 (PLK1)
inhibitor onvansertib in metastatic castration resistant prostate cancer
(mCRPC) patients
Session Title:
Biomarkers Predictive of Therapeutic Benefit 1
Session Date:
April 11, 2022
Session Start Time:
9:00 AM CT
Location:
Poster Section 30
This abstract describes genomic and transcriptomic analyses from the ongoing Phase 2 trial of onvansertib in combination with Zytiga (abiraterone)/prednisone in mCRPC patients with early abiraterone resistance. Collectively, these analyses suggest that alterations in PTEN and MTOR, two key genes of the PI3K signaling pathway, are potential biomarkers for sensitivity to onvansertib-abiraterone combination therapy in mCRPC patients with early abiraterone-resistance.
Poster Title:
Combining PARP inhibition with the polo-like kinase 1 (PLK1)
inhibitor onvansertib overcomes PARP inhibitor resistance
Drug Resistance and Reversal of Resistance
Session Date:
April 12, 2022
Session Start Time:
1:30 PM CT
Location:
Poster Section 22
This abstract includes preclinical data that demonstrate the potent anti-tumor activity of onvansertib combined with the PARP inhibitor olaparib in olaparib-resistant ovarian cancer models. Additional preclinical studies are ongoing to further assess the potential of the onvansertib-olaparib combination in models of ovarian, prostate, pancreatic and breast cancer.